Skip to main content

Table 3 Description of patient ascites samples used for quantitative Real-Time PCR analysis

From: A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer

Sample no.

Diagnosis

Silverberg grade

FIGO stage

Treatment

Age

Survival

Chemonaive

      

1

Serous Cystadenoma/ Early Serous Borderline

NA

NA

None

64

NA

2

Serous Cystadenocarcinoma

NA

III

None

65

1 year 5 monthsa

3

Serous Papillary Carcinoma

G3

NA

None

NA

NA

4

Papillary Serous Cystadenocarcinoma

G3

IIIc

None

48

1 year 6 monthsa

5

Serous Cystadenocarcinoma NOS

G3

IIIa

None

51

1 year 3 monthsa

6

Serous Cystadenocarcinoma NOS

G3

NA

None

71

1 year 1 montha

Recurrent

      

1

Serous Cystadenocarcinoma NOS

G3

IIc

Carboplatin and Paclitaxel 2 Cycles

64

5 months until death

2

Adenocarcinoma NOS

NA

IV

Carboplatin and Paclitaxel 6 Cycles

67

2 years 8 months until death

3

Serous Cystadenocarcinoma NOS

G3

IIIc

Carboplatin/Paclitaxel/ Bevacizumab-VGEF Inhibitor (ICON7 Trial) 18 Cycles

55

5 years 6 months until death

4

Papillary Serous Cystadenocarcinoma

G3

IIIc

Carboplatin and Paclitaxel 6 Cycles

59

3 years 2 months until death

Gemicitabine and Cisplatin

5

Papillary Serous Cystadenocarcinoma

G3

IIIc

Carboplatin/Paclitaxel/BIBF1120- Angiogenesis Inhibitor (OVAR12 Study)

46

3 years 11 months ALC

6

Serous Cystadenocarcinoma NOS

G3

IV

Bevacizumab 1 cycle

57

4 years 3 months

Paclitaxel and Cisplatin 6 cycles

 

ALC

Doxorubicin Pegylated Liposomal 6 cycles

  1. NOS Not Otherwise Specified, ALC At Last Contact
  2. aindicates patients were alive at the time of manuscript preparation